Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.02 -0.07% 28.98 314,390 10:39:49
Bid Price Offer Price High Price Low Price Open Price
27.02 28.98 28.98 28.00 28.02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -57.86 -24.28 58
Last Trade Time Trade Type Trade Size Trade Price Currency
10:03:01 AT 1,000 28.98 GBX

Synairgen (SNG) Latest News (1)

More Synairgen News
Synairgen Investors    Synairgen Takeover Rumours

Synairgen (SNG) Discussions and Chat

Synairgen (SNG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Synairgen trades in real-time

Synairgen (SNG) Top Chat Posts

Synairgen Daily Update: Synairgen Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 29p.
Synairgen Plc has a 4 week average price of 25.14p and a 12 week average price of 22.02p.
The 1 year high share price is 223.80p while the 1 year low share price is currently 11.12p.
There are currently 201,374,975 shares in issue and the average daily traded volume is 678,894 shares. The market capitalisation of Synairgen Plc is £58,358,467.76.
daffodil4: Price: 29.90 No Opinion RE: All gone quietToday 13:27 Positive AGM overall. Full team being retained as there is so much work to be done and so many conversations being had with platform trials and potential partners. Focus is on getting onto a trial and getting more data - Simon Shaw said this will improve the attractiveness of SNG to BP. SSH quite vocal when long covid was mentioned. Very excited about the potential for interferon. Phil Monk said long covid data wont be included in first peer reviewed paper. It will follow in due course... Simon Shaw said their is a head of steam building with conversations 'across the pond'. SSH said that covid is particularly unpredictable, unlike flu and rsv. This means that a new nasty variant could materialise at any moment from anyone infected. The medical world are still very worried about covid and omicron has given people/governments a false sense of security. SSH said vaccine evasion is a case of when not and not if. He also said we are due to a big wave of flu (potentially this winter) as our overall flu immunity has diminished after 2 years of masking and distancing. A significant proportion of covid patients that are hospitalised are also infected by other viruses due to covid impacting their immune system. SNG001 treats all respiratory viruses a patient is suffering with - unlike other covid treatments
nobbygnome: As I said before Activ-2 is a sideshow. Yes it may well cause a rise in the share price but it’s not that important for the company. And my comment about flu was not related to SNG but just the stupidity of saying we should just treat it like flu.
bi11y ray va1entine: The Activ 2 announcement won't give much indication of what a new trial would do for the share price. The Activ 2 inclusion RNS was released on January 25th 2021. But infection rates were up and down in the UK, so the share price was as well.
shoots101: Anyone recall the impact on the share price when sng first got accepted onto Active as I'm not expecting big rises but still a step in the right direction
shoots101: Hazel this isn't a game whereby the share prices go high if we think positive. Doesn't work like that. I'm a half full type and mix like minded types but this is investing and the share price doesn't lie. Look at it ... it was over £2 and now 30p so tell me the positive please ? Love to hear it
shoots101: For those on LSE who still have not woken up. If SNG had good data from deep drive the share price will start to rise way before next week. I'm trying to help the kids on there that's all. The data would absolutely leak to those closely involved. It's very naive to think otherwise as is the way with all stocks awaiting news etc. They have 15 minutes. That's it. So if it was positive firstly they would announce it early as poss and secondly
i53: An interesting conspiracy theory. As the trials to date have shown, SNG001 is still to be fully proven as a strategic drug in the treatment of Covid 19, let alone a cost effective one. However, there has been sufficient data and market interest to strongly suggest it has the potential. Large pharmas may see a place for SNG001 long term, but for some may also see SNG001 as a potential threat to their own line of drug development. The cost of trialling their own drugs could probably limit the budget spend outside of their own research, and making an outright T/O inappropriate short term. This, however, would still leave SNG001 as a potential threat if the trial data were to prove the drug successful. Meantime we see a large and persistent investment taking place by Polygon. But the big question still remains what is their end game strategy, or who are they accumulating on behalf of? To date everyone has speculated that they are accumulating to a percentage significant enough to dictate how SNG is moved on and at what price. However, the other possibility that hasn't been discussed is that, the threat of SNG001 as an alternative treatment could be serious enough for a another pharma to take a large enough stake, not necessarily to swallow SNG with a buyout, but moreover, to prevent it from compromising the potential success of their own drug development. Taking a large controlling stake, as costly as that may be, is significantly less than making a full T/O bid for SNG as a whole In effect the controlling stake would then become a Blocking Stake dictating the fate of SNG001 effectively placing it in the pending tray, for possible progression or quiet retirement. Not my view, but as i've not seen it discussed before, definitely food for thought
pwhite73: srpactive - "Yes, why was the share price destroyed yesterday when a good rns was about to be released the next morning, lol." The share price was destroyed yesterday because the raw facts about the cessation of the Activ 2 P3 trial had been placed in the public domain. SNG had not yet had time to put a positive spin on it. Overnight they've worked on something to convince mug PIs nothing has failed and all pauses are only temporary. Yes you might get another holdings RNS but as I posted yesterday it would not surprise me if the holder is behind the next heavily discounted fundraise.
agent x11: Looks like the Game is over. The covid scam is over. Synairgen plc Update on SNG001 03/03/2022 7:00am UK Regulatory (RNS & others) Synairgen (LSE:SNG) Intraday Stock Chart Thursday 3 March 2022 RNS Number : 4606D Synairgen plc 03 March 2022 Synairgen plc ('Synairgen' or the 'Company') Update on SNG001 in the ACTIV-2 Phase 3 trial for COVID-19 and on SNG001 activity against Delta and Omicron variants Southampton, UK - 03 March 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces an update on SNG001 in the ACTIV-2 Phase 3 trial for COVID-19 and on SNG001 activity against Delta and Omicron variants. ACTIV-2 Phase 3 trial for COVID-19 Due to the need to modify the study design in light of the emergence of the Omicron variant of SARS-CoV-2, the US National Institutes of Health (NIH) ACTIV-2 trial team has asked Synairgen to temporarily pause activities to prepare clinical supplies for ACTIV-2 Phase 3 until the timeline for the activation of this agent in the trial is clarified. Synairgen continues to await the Phase 2 data from the US NIH ACTIV-2 trial in home-based COVID-19 participants, expected by mid-year. Update on SNG001 and Delta and Omicron variants The Company also announced that in vitro studies conducted at Viroclinics-DDL in the Netherlands have shown that SNG001 has potent antiviral activity against SARS-CoV-2 Delta and Omicron variants at concentrations that are readily achievable following inhaled delivery of interferon beta. Further SPRINTER Phase 3 analysis As announced on 21 February 2022, Synairgen is in the process of analysing the topline and full dataset from the SPRINTER Phase 3 study in order to better understand all of the findings. The findings of this analysis will be announced without delay once complete in accordance with regulatory obligations and presented and/or published in a peer-review journal. The SPRINTER trial pointed to an encouraging trend in prevention of progression to severe disease and death (36% reduction in the pre-defined per protocol population), which the Company and its clinical advisors strongly believe merits further investigation in a platf orm trial which the Company is actively investigating.
tickboo: really good post from Brand on lse earlier today:-Brand --- Some Positivity --- Today 12:19* sprinter phase 3 failed to meet endpoints in a multi country trial that met the delta wave hand an improved SOC halfway through, yet did show a 40% reduction in progression to severe disease and death, it did not in anyway show SNG001 ineffective.* SNG001 has been proven to be safe and effective in multiple trials - this is incredibly important considering the history of subcutaneous administration of INF.* Activ-2 phase 3 remains in play, with efficacy data from phase 2 due in the coming weeks*Further with Activ, the trial design allows for data from other trials to be considered - The US govt is only interested in finding effective thereputics for Covid, not anyone's share price - they wouldn't have progressed it if they didn't believe it worked.* The company is (or will be soon in the case of A2P2) in possession of a large amount of data on SNG001 vs Covid, which again has shown the treatment to be safe and effective.* SNG001 is effective against all respiratory viruses, this is not a one trick pony, approval will lead to a revolution in respiratory health.* We have still not seen any data on SNG001 Vs Long Covid, which given its known effectiveness, could be exceptional and could pull data from across the different trials run over the last 2 years ensuring any conclusions are suitably powered.* We look to have a genuine heavy hitting consultant assisting the company in Ray Jordan, who most recently played a pivotal role in making moderna one of the most well known (and profitable) names in medicine* Much has been made of the proposed cost of treatment with SNG001, but INFb production has been established for many years and the nebulisers are reusable, adding scale to production could well bring the cost to levels below other anti-virals on the market.* Thanks to our friends at Polygon, SNG was incredibly undervalued at 350m GBP before last Mondays RNS - if we get an RNS with A2P3 first patient dosed and a BARDA grant as per SAB in the coming weeks, where does that put the SP?I saw a poster on here last night say they were settling in for the next 12-18 months and I would echo those sentiments - TBF I was only looking at slicing 5-10% at the most on a positive RNS and holding the rest. yes I am still massively disappointed P3 s#!t the bed - but it was the trial that failed not the drug.Onwards.
Synairgen share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220706 09:54:53